玻璃体腔注射贝伐珠单抗治疗增殖性糖尿病视网膜病变对肾小球滤过率的影响
该研究回顾性分析了60例接受玻璃体腔贝伐珠单抗注射的增殖性糖尿病视网膜病变患者,评估重复注射与肾小球滤过率(GFR)长期下降的关联。结果显示注射次数与终末GFR、GFR下降值或GFR下降百分比均无显著关联(P=0.72、P=0.88、P=0.49)。结论认为治疗剂量的玻璃体腔贝伐珠单抗注射次数增加与GFR降低无关,支持玻璃体腔抗血管内皮生长因子药物对肾脏安全。
要点
- 患者平均接受3.6次注射(范围1至17次),平均基线GFR为76±38 mL/min,终末GFR为63±39 mL/min。
- 注射次数与终末GFR(P=0.72)、GFR下降(P=0.88)及GFR下降百分比(P=0.49)均无显著关联。
- 治疗剂量的玻璃体腔贝伐珠单抗注射次数增加与GFR降低无关,支持抗VEGF药物对肾脏安全。
核心结论
- 治疗剂量的玻璃体腔贝伐珠单抗注射次数增加与增殖性糖尿病视网膜病变患者的GFR降低无关,本研究支持玻璃体腔抗血管内皮生长因子药物对肾脏安全。
研究设计与样本
- 回顾性查阅300份病历,其中60例患者符合纳入标准。
- 纳入标准为接受至少一次贝伐珠单抗注射、初次注射前有基线GFR、基线后6至24个月有终末GFR。
- 分析中控制了基线至终末GFR测量之间的时间、血压、糖化血红蛋白A1C、种族、性别、年龄以及血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂的使用。
- 采用逐步多元线性回归进行显著性检验,显著性阈值设为5%,所有检验均为双侧。
主要发现
- 患者接受1至17次注射(平均3.6次),平均基线GFR为76±38 mL/min,终末GFR为63±39 mL/min。
- 注射次数与终末GFR无关联(P=0.72)。
- 注射次数与GFR下降无关联(P=0.88)。
- 注射次数与GFR下降百分比无关联(P=0.49)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess whether the repeated use of intravitreal bevacizumab injections in treatment of proliferative diabetic retinopathy is associated with a long-term decline in the glomerular filtration rate (GFR). METHODS: Three hundred charts were retrospectively reviewed, of which 60 patients met the criteria for inclusion. The criteria were as follows: reception of at least one bevacizumab injection, baseline GFR before initial bevacizumab injection, and end GFR 6 to 24 months after baseline. Analysis controlled for time between baseline and end GFR measurements, blood pressure, hemoglobin A1C, race, sex, age, and use of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. Significance testing was performed with step-wise multiple linear regression. The significance threshold was 5%, and all tests were two-sided. RESULTS: Patients received a range of 1 to 17 injections (average 3.6). The average baseline GFR was 76 ± 38 mL/minute, and the end GFR was 63 ± 39 mL/min. The number of injections patients received was not associated with end GFR ( P = 0.72), GFR reduction ( P = 0.88), or percent GFR reduction ( P = 0.49). CONCLUSION: Increased number of intravitreal bevacizumab injections at therapeutic dosage was not associated with reduced GFR in patients with proliferative diabetic retinopathy. This study supports that intravitreal antivascular endothelial growth factor agents are renally safe.
引用
- Camp DA, Price DA, Neiweem AE, et al. EFFECTS OF INTRAVITREAL BEVACIZUMAB THERAPY ON GLOMERULAR FILTRATION RATES IN PATIENTS TREATED FOR PROLIFERATIVE DIABETIC RETINOPATHY. Retina. 2022. PMID: 35976221. doi:10.1097/IAE.0000000000003562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。